Table 1 In silico identified P-gp inhibitors reverse MDR phenotype of ovarian cancer cell line.

		paclitaxel IC₅₀ (nmol/L)	Fold sensitization	vinblastine IC₅₀ (nmol/L)	Fold sensitization
A2780ADR	paclitaxel/vinblastine only	2146		361
	+ compound 29
	5 μM	121	18	52	7
	10 μM	42	52	16	22
	25 μM	7	308
	+ compound 34
	5 μM	57	38	42	9
	10 μM	20	107	12	31
	25 μM	4	528
	+ compound 45
	5 μM	122	18	49	7
	10 μM	90	24	34	11
	25 μM	10	225
	+ verapamil
	5 μM	53	41	19	19
	10 μM	22	99	6	58
	25 μM	8	265
	+ novobiocin
	60 μM			475	1
	+ probenecid
	250 μM			525	1
A2780	paclitaxel/vinblastine only	5		15
	+ compound 29
	10 μM	5	1	14	1
	+ compound 34
	10 μM	5	1	14	1
	+ compound 45
	10 μM	4	1	16	1
	+ verapamil
	10 μM	5	1	13	1

IC₅₀ concentrations of chemotherapeutics which resulted in 50% decrease in A2780ADR viability were calculated from data as shown in Fig. 1, S3 and S4 using a nonlinear, four-parameter curve fitting procedure.

Quick links

Search